Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Am J Health Syst Pharm ; 75(10): 622-626, 2018 May 15.
Artigo em Inglês | MEDLINE | ID: mdl-29748300

RESUMO

PURPOSE: Results of an assessment of the chemical stability of isoniazid injection in 0.9% sodium chloride injection and 5% dextrose injection are reported. METHODS: Triplicate solutions of isoniazid (0.5 and 6.0 mg/mL) in the 2 diluents were prepared in ethylene and propylene copolymer i.v. containers and stored under light protection at room temperature (20-25 °C) or under refrigeration (2-8 °C). Standard aliquots were removed from each solution at time points up to 72 hours and analyzed via high-performance liquid chromatography (HPLC). Stability was defined as retention of >90% of the initial isoniazid concentration; pH, osmolality, and visual appearance were assessed. RESULTS: Isoniazid 0.5- and 6.0-mg/mL solutions in 0.9% sodium chloride injection were stable for up to 72 hours at room temperature or under refrigeration. HPLC analysis of isoniazid 0.5-mg/mL solutions in 5% dextrose injection revealed a decrease to less than 90% of the initial concentration at 8 hours at room temperature and at 30 hours under refrigeration. Isoniazid 6.0-mg/mL solutions in 5% dextrose injection were stable for 24 hours at room temperature and for 48 hours under refrigeration. The pH, osmolality, and visual appearance of the solutions were not affected. CONCLUSION: Isoniazid solutions of 0.5 and 6.0 mg/mL in 0.9% sodium chloride injection were stable under light protection for up to 72 hours when stored at room temperature or under refrigeration. Isoniazid injection was less stable in 5% dextrose injection, especially at a concentration of 0.5 mg/mL at room temperature.


Assuntos
Antituberculosos/administração & dosagem , Química Farmacêutica/métodos , Composição de Medicamentos/métodos , Isoniazida/administração & dosagem , Antituberculosos/química , Cromatografia Líquida de Alta Pressão , Embalagem de Medicamentos , Estabilidade de Medicamentos , Armazenamento de Medicamentos , Glucose/química , Injeções , Isoniazida/química , Veículos Farmacêuticos/química , Refrigeração , Cloreto de Sódio/química , Temperatura , Fatores de Tempo
2.
Blood ; 123(15): 2308-16, 2014 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-24523241

RESUMO

Warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome is a rare immunodeficiency disorder caused by gain-of-function mutations in the G protein-coupled chemokine receptor CXCR4. The CXCR4 antagonist plerixafor, which is approved by the US Food and Drug Administration (FDA) for stem cell mobilization in cancer and administered for that indication at 0.24 mg/kg, has been shown in short-term (1- to 2-week) phase 1 dose-escalation studies to correct neutropenia and other cytopenias in WHIM syndrome. However, long-term safety and long-term hematologic and clinical efficacy data are lacking. Here we report results from the first long-term clinical trial of plerixafor in any disease, in which 3 adults with WHIM syndrome self-injected 0.01 to 0.02 mg/kg (4% to 8% of the FDA-approved dose) subcutaneously twice daily for 6 months. Circulating leukocytes were durably increased throughout the trial in all patients, and this was associated with fewer infections and improvement in warts in combination with imiquimod; however, immunoglobulin levels and specific vaccine responses were not fully restored. No drug-associated side effects were observed. These results provide preliminary evidence for the safety and clinical efficacy of long-term, low-dose plerixafor in WHIM syndrome and support its continued study as mechanism-based therapy in this disease. The ClinicalTrials.gov identifier for this study is NCT00967785.


Assuntos
Compostos Heterocíclicos/uso terapêutico , Síndromes de Imunodeficiência/tratamento farmacológico , Receptores CXCR4/antagonistas & inibidores , Verrugas/tratamento farmacológico , Adulto , Benzilaminas , Ciclamos , Feminino , Citometria de Fluxo , Compostos Heterocíclicos/administração & dosagem , Compostos Heterocíclicos/farmacocinética , Humanos , Masculino , Pessoa de Meia-Idade , Doenças da Imunodeficiência Primária , Fatores de Tempo
3.
Am J Health Syst Pharm ; 70(5): 439-42, 2013 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-23413168

RESUMO

PURPOSE: The 24-hour stability of alemtuzumab solutions prepared at concentrations not included in the product label and stored in glass or polyolefin containers at room temperature was evaluated. METHODS: Triplicate solutions of alemtuzumab (6.67, 40, and 120 µg/mL) in 0.9% sodium chloride were prepared in either glass bottles or polyolefin containers and stored at room temperature under normal fluorescent lighting conditions. The solutions were analyzed by a validated stability-indicating high-performance liquid chromatography (HPLC) assay at time zero and 8, 14, and 24 hours after preparation; solution pH values were measured and the containers visually inspected at all time points. Stability was defined as the retention of ≥90% of the initial alemtuzumab concentration. RESULTS: HPLC analysis indicated that the percentage of the initial alemtuzumab concentration retained was >90% for all solutions evaluated, with no significant changes over the study period. The most dilute alemtuzumab solution (6.67 µg/mL) showed some degradation (91% of the initial concentration retained at hour 24), whereas the retained concentration was >99% for all other preparations throughout the study period. Solution pH values varied by drug concentration but did not change significantly over 24 hours. No evidence of particle formation was detected in any solution by visual inspection at any time during the study. CONCLUSION: Solutions of alemtuzumab 6.67 µg/mL stored in glass bottles and solutions of 40 and 120 µg/mL stored in polyolefin containers were stable for at least 24 hours at room temperature.


Assuntos
Anticorpos Monoclonais Humanizados/química , Temperatura , Alemtuzumab , Anticorpos Monoclonais Humanizados/análise , Cromatografia Líquida de Alta Pressão/normas , Estabilidade de Medicamentos , Armazenamento de Medicamentos/normas , Vidro/análise , Vidro/normas , Soluções Farmacêuticas/análise , Soluções Farmacêuticas/normas , Polienos/análise , Polienos/normas
4.
Neurology ; 80(10): 933-40, 2013 Mar 05.
Artigo em Inglês | MEDLINE | ID: mdl-23408867

RESUMO

OBJECTIVE: To assess safety and efficacy of an oral, single, low dose of octanoic acid (OA) in subjects with alcohol-responsive essential tremor (ET). METHODS: We conducted a double-blind, placebo-controlled, crossover, phase I/II clinical trial evaluating the effect of 4 mg/kg OA in 19 subjects with ET. The primary outcome was accelerometric postural tremor power of the dominant hand 80 minutes after administration. Secondary outcomes included digital spiral analysis, pharmacokinetic sampling, as well as safety measures. RESULTS: OA was safe and well tolerated. Nonserious adverse events were mild (Common Terminology Criteria for Adverse Events grade 1) and equally present after OA and placebo. At the primary outcome, OA effects were not different from placebo. Secondary outcome analyses of digital spiral analysis, comparison across the entire time course in weighted and nonweighted accelerometry, as well as nondominant hand tremor power did not show a benefit of OA over placebo. The analysis of individual time points showed that OA improved tremor at 300 minutes (dominant hand, F = 5.49, p = 0.032 vs placebo), with a maximum benefit at 180 minutes after OA (both hands, F = 6.1, p = 0.025). CONCLUSIONS: Although the effects of OA and placebo at the primary outcome were not different, secondary outcome measures suggest superiority of OA in reducing tremor at later time points, warranting further trials at higher dose levels. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that a single 4-mg/kg dose of OA is not effective in reducing postural tremor in patients with ET at a primary outcome of 80 minutes, but is effective for a secondary outcome after 180 minutes.


Assuntos
Bebidas Alcoólicas , Caprilatos/uso terapêutico , Tremor Essencial/tratamento farmacológico , Caprilatos/farmacocinética , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Tempo
5.
Neurotherapeutics ; 8(4): 753-62, 2011 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-21594724

RESUMO

Existing therapeutic options for management of essential tremor are frequently limited by poor efficacy and adverse effects. Likely the most potent tremor suppressant used is ethanol, although its use is prohibitive due to a brief therapeutic window, and the obvious implications of excessive alcohol use. Longer-chain alcohols have been shown to suppress tremor in harmaline animal models, and appear to be safe and well tolerated in 2 prior studies in humans. Here we report on the findings of a phase I/II study of 1-octanol designed to explore pharmacokinetics, efficacy, and safety. The most significant finding was the identification of octanoic acid as the product of rapid 1-octanol metabolism. Furthermore, the temporal profile of efficacy closely matches the plasma concentration of octanoic acid. Therefore, these findings identify a novel class of compound (e.g., carboxylic acids) with tremor suppressive properties in ET. Administration of 1-octanol also appears to be safe based on various measures collected. Essential tremor (ET) is the most common tremor disorder, with tremors occurring during static posturing or movement. These tremors are known to briefly improve in many cases after alcohol (ethanol) consumption. Two previous studies of a longer chain alcohol, 1-octanol, have demonstrated longer duration tremor-suppressive effects without the occurrence of intoxication. The aim of this study was to characterize the pharmacokinetics of 1-octanol and its primary metabolite octanoic acid using two formulations, along with additional safety and efficacy measures. Participants with proven ethanol-responsive ET were recruited into 1 of 2 parts: (part A) a dose escalation study (1-64 mg/kg; n = 4), and (part B) a fixed dose (64 mg/kg; n = 10) balanced, open-label crossover design. Two participants in part B then completed an exploratory part C evaluating 128 mg/kg.Plasma samples were collected at 10 intervals during a 6-hour period postingestion. Efficacy was assessed using spirography, whereas safety was assessed with electrocardiograms, vital signs, adverse effects surveys, and an intoxication assessment. Plasma concentrations of 1-octanol were detectable at low levels whereas octanoic acid (OA) concentrations were approximately 100-fold higher. The half-life of OA was 87.6 minutes. This was matched by a clinical reduction in tremor severity of 32% at 90 minutes, assessed using spirography. The safety profile was favorable, with the most commonly reported adverse effect being dysgeusia (38%). Early detection and higher plasma concentrations of OA are a product of rapid metabolism of 1-octanol.OA pharmacokinetics mirrored the timing of clinical improvement. These findings provide preliminary evidence for a new class of compound that may be effective in the treatment of ET.


Assuntos
1-Octanol , Tremor Essencial/sangue , Tremor Essencial/tratamento farmacológico , Solventes , 1-Octanol/administração & dosagem , 1-Octanol/sangue , 1-Octanol/farmacocinética , Administração Oral , Idoso , Caprilatos/sangue , Química Farmacêutica , Estudos Cross-Over , Relação Dose-Resposta a Droga , Feminino , Frequência Cardíaca/efeitos dos fármacos , Humanos , Masculino , Pessoa de Meia-Idade , Solventes/administração & dosagem , Solventes/metabolismo , Solventes/farmacocinética , Fatores de Tempo , Resultado do Tratamento
6.
Am J Health Syst Pharm ; 67(7): 562-5, 2010 Apr 01.
Artigo em Inglês | MEDLINE | ID: mdl-20237384

RESUMO

PURPOSE: The physical compatibility of magnesium sulfate and sodium bicarbonate in a pharmacy-compounded hemofiltration solution was assessed. METHODS: Two bicarbonate-buffered hemofiltration solutions (low- and high-magnesium formulations) were compounded in triplicate. The concentrations of magnesium (15 meq/L) and sodium bicarbonate (50 meq/L) in the high-magnesium formulation were chosen to be somewhat below the concentrations reported as being incompatible in a popular reference. The six hemofiltration bags were stored at 22-25 degrees C without protection from light for 48 hours. Physical compatibility was assessed by visual inspection and microscopy. The pH of the solutions was assayed 3-4 and 52-53 hours after compounding. Electrolyte and glucose concentrations of the solutions were assayed at 3-4 and 50-51 hours after preparation. RESULTS: No particulate matter was observed by visual or microscopic inspection in the compounded hemofiltration solutions at 48 hours. The mean +/- S.D. pH values of the low-magnesium solutions were 8.01 +/- 0.02 and 8.04 +/- 0.02 at 3-4 and 52-53 hours after compounding, respectively. The mean +/- S.D. pH values of the high-magnesium solutions were 7.96 +/- 0.02 and 7.98 +/- 0.01 at 3-4 and 52-53 hours after compounding, respectively. The electrolyte and glucose concentrations in the low- and high-magnesium solutions were similar 3-4 and 50-51 hours after preparation. CONCLUSION: Magnesium sulfate 1.5 meq/L and sodium bicarbonate 50 meq/L were physically compatible in a pharmacy-compounded hemofiltration solution for 48 hours when stored at 22-25 degrees C without protection from light.


Assuntos
Soluções para Diálise/química , Hemofiltração , Sulfato de Magnésio/química , Bicarbonato de Sódio/química , Composição de Medicamentos , Incompatibilidade de Medicamentos , Armazenamento de Medicamentos , Eletrólitos/análise , Glucose/análise , Concentração de Íons de Hidrogênio , Soluções Farmacêuticas , Serviço de Farmácia Hospitalar
7.
Vaccine ; 24(23): 5064-72, 2006 Jun 05.
Artigo em Inglês | MEDLINE | ID: mdl-16621178

RESUMO

Although replication-competent adenovirus (Ad) vectors are promising in AIDS vaccine design, their safety in immune compromised hosts is unknown. To initially address this question, enteric-coated tablets containing a replicating Ad vector were orally administered to SHIV- and SIV-infected rhesus macaques with normal, intermediate or low CD4 T cell counts and stable disease. The vector was detected within a week after tablet administration in stools of all animals but not in nasal secretions, indicating no spread of virus to the upper respiratory tract. CD4 T cell counts and viral loads remained stable in all animals and no signs of fever, weight loss, or other clinical symptoms of Ad-induced disease were observed during 10 weeks of follow-up. Oral delivery of the replicating Ad vector was safe and well tolerated by SHIV- and SIV-infected hosts. Oral enteric-coated tablets may prove safe for administering replicating Ad-vectored vaccines in areas with high HIV prevalence.


Assuntos
Vacinas contra a AIDS/efeitos adversos , Adenovírus Humanos/genética , Adenovírus Humanos/fisiologia , Macaca mulatta/fisiologia , Macaca mulatta/virologia , Síndrome de Imunodeficiência Adquirida dos Símios/virologia , Replicação Viral , Vacinas contra a AIDS/genética , Vacinas contra a AIDS/metabolismo , Administração Oral , Animais , Anticorpos Antivirais/sangue , Temperatura Corporal , Contagem de Linfócito CD4 , Vetores Genéticos/genética , Vetores Genéticos/fisiologia , Síndrome de Imunodeficiência Adquirida dos Símios/imunologia , Viremia
8.
J Pharm Sci ; 95(1): 108-15, 2006 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-16315224

RESUMO

PROLI/NO is an agent of structure XN(O)==NONa (X = L-prolyl) whose 2-s half-life for nitric oxide (NO) release at physiological pH makes it an excellent prodrug for localizing NO's therapeutic effects at the site of application, but a difficult one to formulate and certify as pure. Despite its extraordinary thermal and hydrolytic instability, however, PROLI/NO could be formulated as an injectable drug by dissolving it in cold 0.1 M sodium hydroxide containing 5% D-mannitol, then quickly ultrafiltering and lyophilizing it in evacuated septum vials. No evidence for decomposition was seen in the contents of these evacuated vials when stored at -20 degrees C over a 140-day observation period, as judged by quantifying NO release in simulated infusate solutions (10 mM carbonate/bicarbonate, pH 10.5). The only hydrolysis products detected were NO, nitrite ion, proline, and N-nitrosoproline, all products of normal human physiological processes.


Assuntos
Doadores de Óxido Nítrico/química , Óxidos de Nitrogênio/química , Pró-Fármacos/química , Prolina/análogos & derivados , Composição de Medicamentos , Armazenamento de Medicamentos , Hidrólise , Injeções Intravenosas , Óxido Nítrico/análise , Doadores de Óxido Nítrico/análise , Óxidos de Nitrogênio/análise , Pró-Fármacos/análise , Prolina/análise , Prolina/química
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA